Two cases of oral steroid and local tacrolimus combination therapy for oral lichen planus ineffective with local steroid therapy

AOKI, YUSUKE; Minabe, Masaki; Iida, Junichiro; Akiyama, Yurie; Hashimoto, Kazuhiko; Kouno, Michiyoshi; Takahashi, Shinichi; Nomura, Takeshi

doi:10.1016/j.ajoms.2022.07.009

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Typical protocols mandate application of topical corticosteroids 2–3 times per day for 1–2 months, with subsequent administration as needed 12. This frequency and duration aim to achieve effective symptom relief while minimising the risk of adverse effects, such as mucosal thinning and secondary candidiasis 13 14. However, it is worth noting that some patients may exhibit inadequate response or develop resistance to topical corticosteroids 15…”

Section: Introductionmentioning

confidence: 99%

Cepharanthine and Oral Lichen Planus Efficacy (COLE) study: protocol for a multicentre randomised controlled study assessing the efficacy and safety of cepharanthine with topical corticosteroids in oral lichen planus

Yagyuu

Isogawa

Yamamoto³

et al. 2023

BMJ Open

View full text Add to dashboard Cite

IntroductionOral lichen planus (OLP) is a chronic, inflammatory oral condition leading to a range of symptoms from mild discomfort to severe pain, affecting patients’ quality of life. Standard therapy involves the use of topical corticosteroids, although some patients respond insufficiently or develop resistance to therapy. We aim to explore if adding cepharanthine, an herbal extract fromStephania cepharanthaHayata, can enhance the efficacy of corticosteroid therapy in symptomatic OLP.Methods and analysisThis open-label, parallel-group, multi-centre, randomised controlled study will be conducted at three Japanese hospitals. It will compare safety and efficacy of integrated oral cepharanthine and corticosteroid therapy versus standard corticosteroid therapy. 50 symptomatic OLP patients will be randomised 1:1 to receive cepharanthine (30 mg/day) plus topical dexamethasone, or topical dexamethasone alone for 8 weeks. The primary outcome will be changed in pain intensity while drinking room-temperature water, measured on a visual analogue scale. The primary outcome is the change in pain intensity from baseline when drinking room-temperature water, evaluated using a visual analogue scale. Secondary outcomes are changes in the longest diameter of the target lesion from baseline to weeks 4 and 8, improvement and deterioration rates according to appearance and severity criteria at weeks 4 and 8, change in pain intensity when drinking room-temperature water from baseline to week 4, changes in pain intensity at rest from baseline to weeks 4 and 8, and the rates of adverse events.Ethics and disseminationThis protocol was approved by the Certified Review Board of Nara Medical University (CRB5200002). Participants will provide informed consent. Results will be disseminated in peer-reviewed journals and conferences.Trial registration numberJapan Registry of Clinical Trials (jRCTs051220130).

show abstract

Section: Introductionmentioning

confidence: 99%